ArticleDiagnostics (Basel, Switzerland)2023
Is the Level of Contrast Enhancement on Contrast-Enhanced Mammography (CEM) Associated with the Presence and Biological Aggressiveness of Breast Cancer?
Article in Diagnostics (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 19 citations in OpenAlex.
- ROI-Based Quantitative Analysis in Contrast-Enhanced Mammography: A Feasibility Study for Reproducible Enhancement Assessment.Diagnostics (Basel, Switzerland) · 2026Article
- How to optimise breast cancer staging with contrast-enhanced mammography: current evidence and clinical implications.Insights into imaging · 2026Review
- Diagnostic performance of contrast-enhanced mammography and MRI for breast non-mass microcalcifications: a novel Malignant Calcification Score in contrast-enhanced mammography.Quantitative imaging in medicine and surgery · 2026Article
- Ground-Glass Enhancement on Contrast-Enhanced Mammography: A CT-Inspired Qualitative Descriptor for Breast Lesion Characterization.Journal of clinical medicine · 2026Article
- Contrast-Enhanced Mammography and Deep Learning-Derived Malignancy Scoring in Breast Cancer Molecular Subtype Assessment.Medicina (Kaunas, Lithuania) · 2026Article
- Predictive deep learning model based on contrast-enhanced mammography for breast cancer diagnosis: a pilot study.BJR artificial intelligence · 2026Article
- Achieving single-contrast administration for enhanced chest CT and contrast-enhanced spectral mammography without compromising diagnostic quality: a comparative study.Cancer imaging : the official publication of the International Cancer Imaging Society · 2025Article
- A head-to-head comparison of breast lesion's conspicuity at contrast-enhanced mammography and contrast-enhanced MRI.European radiology · 2025Article
- Morphodynamic Features of Contrast-Enhanced Mammography and Their Correlation with Breast Cancer Histopathology.Journal of imaging · 2025Article
- Lesion Conspicuity in Contrast-Enhanced Mammography: A Retrospective Analysis of Tumor Characteristics.Cancers · 2025Article
- Does Contrast-Enhanced Mammography Outperform Digital Breast Tomosynthesis for Detection and Characterization of Breast Lesions or Vice Versa?Indian journal of surgical oncology · 2025Article
- Correlation between the CEM imaging characteristics and different molecular subtypes of breast cancer.Breast (Edinburgh, Scotland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is limited information about whether the level of enhancement on contrast-enhanced mammography (CEM) can be used to predict malignancy. The purpose of this study was to correlate the level of enhancement with the presence of malignancy and breast cancer (BC) aggressiveness on CEM. This IRB-approved, cross-sectional, retrospective study included consecutive patients examined with CEM for unclear or suspicious findings on mammography or ultrasound. Excluded were examinations performed after biopsy or during neoadjuvant treatment for BC. Three breast radiologists who were blinded to patient data evaluated the images. The enhancement intensity was rated from 0 (no enhancement) to 3 (distinct enhancement). ROC analysis was performed. Sensitivity and negative likelihood ratio (LR-) were calculated after dichotomizing enhancement intensity as negative (0) versus positive (1-3). A total of 156 lesions (93 malignant, 63 benign) in 145 patients (mean age 59 ± 11.6 years) were included. The mean ROC curve was 0.827. Mean sensitivity was 95.4%. Mean LR- was 0.12%. Invasive cancer presented predominantly (61.8%) with distinct enhancement. A lack of enhancement was mainly observed for ductal carcinoma in situ. Stronger enhancement intensity was positively correlated with cancer aggressiveness, but the absence of enhancement should not be used to downgrade suspicious calcifications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.